非酒精性脂肪性肝炎中纤维化进展与逆转的决定因素
综述阐述非酒精性脂肪性肝炎(NASH)中肝纤维化进展至肝硬化的决定因素,涉及生活方式、遗传表观遗传及肝内外合并症等多因素;肝细胞脂性凋亡驱动纤维化进展,活化的肝星状细胞等为纤维化效应细胞和药物靶点;新型血清生物标志物和影像方法有助于检测、分层和随访,并促进抗纤维化药物研发。
要点
- NASH中进展至肝硬化较其他慢性肝病更难预测,与生活方式、遗传表观遗传及合并症等多因素相关。
- 肝细胞脂性凋亡是纤维化进展的关键驱动力,活化的肝星状细胞等为纤维化效应细胞和药物靶点。
- 新型高灵敏血清生物标志物和影像方法可评估纤维化动态,改善检测、分层和随访。
核心结论
- NASH中纤维化进展由多因素决定,肝细胞脂性凋亡驱动进展,活化的肝星状细胞等为纤维化效应细胞和药物靶点;新型非侵入性工具将促进抗纤维化药物研发和个体化治疗。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- NASH中进展至肝硬化较其他慢性肝病更不可预测,与生活方式和营养、多种遗传和表观遗传因素及肝内外合并症相关。
- NASH中纤维化生成与经典炎症相关但间接耦合,纤维化进展由反复修复期驱动。
- 肝细胞脂性凋亡是纤维化进展的关键驱动力,活化的肝星状细胞、肌成纤维细胞、胆管细胞、巨噬细胞和病理性细胞外基质成分是主要纤维化效应细胞。
- 新型高灵敏度和特异性的血清生物标志物和影像方法可评估NASH中肝纤维化动态,改善进展性NASH患者的检测、分层和随访。
- 这些非侵入性工具通过允许设计精简的概念验证研究和开发针对快速纤维化进展或晚期疾病患者的个体化抗纤维化治疗,促进抗纤维化药物的临床开发。
关键数值与推荐
- 原文未报告具体标准或数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cirrhosis has become the major liver-related clinical endpoint in non-alcoholic steatohepatitis (NASH). However, progression to cirrhosis is less predictable in NASH than in other chronic liver diseases. This is due to the complex and multifactorial aetiology of NASH, which is determined by lifestyle and nutrition, multiple genetic and epigenetic factors, and a prominent role of hepatic and extrahepatic comorbidities. Thus, modest changes in these cofactors can also induce fibrosis regression, at least in patients with precirrhotic liver disease. Fibrogenesis in NASH correlates with, but is indirectly coupled to, classical inflammation, since fibrosis progression is driven by repetitive periods of repair. While hepatocyte lipoapoptosis is a key driving force of fibrosis progression, activated hepatic stellate cells, myofibroblasts, cholangiocytes, macrophages and components of the pathological extracellular matrix are major fibrogenic effectors and thus pharmacological targets for therapies aimed at inhibition of fibrosis progression or induction of fibrosis reversal. The advent of novel, highly sensitive and specific serum biomarkers and imaging methods to assess the dynamics of liver fibrosis in NASH will improve detection, stratification and follow-up of patients with progressive NASH . These non-invasive tools will also promote the clinical development of antifibrotic drugs, by permitting the design of lean proof-of-concept studies, and enabling development of a personalised antifibrotic therapy for patients with rapid fibrosis progression or advanced disease.
引用
- Schuppan D, Surabattula R, Wang XY, et al. Determinants of fibrosis progression and regression in NASH. J Hepatol. 2017. PMID: 29154966. doi:10.1016/j.jhep.2017.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。